IHVR-19029

Cat. No.:	HY-124662		
CAS No.:	1447464-73	-4	
Molecular Formula:	$C_{23}H_{45}N_{3}O_{5}$		
Molecular Weight:	443.62		
Target:	Glucosidase; Flavivirus; Dengue virus		
Pathway:	Metabolic Enzyme/Protease; Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

®

MedChemExpress

SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.2542 mL	11.2709 mL	22.5418 mL		
		5 mM	0.4508 mL	2.2542 mL	4.5084 mL		
		10 mM	0.2254 mL	1.1271 mL	2.2542 mL		
	Please refer to the so	lubility information to select the app	propriate solvent.				
Vivo		one by one: 10% DMSO >> 40% PEC g/mL (5.64 mM); Clear solution	G300 >> 5% Tween-8) >> 45% saline			
Solubility: ≥ 2.5 m 3. Add each solvent		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution					
	ent one by one: 10% DMSO >> 90% corn oil 5 mg/mL (5.64 mM); Clear solution						

BIOLOGICAL ACTIVITY				
Description	IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC ₅₀ of 0.48 µM for ER a- glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir (HY-14768) improves the antiviral efficacy ^{[1][2][3][4]} .			
In Vitro	IHVR-19029 efficiently inhibits Bovine viral diarrhea virus (BVDV), Tacaribe virus (TCRV) and Dengue virus (DENV) with EC ₅₀ s of 0.25, 0.74, and 1.25 μM, respectively ^[2] .The combination of IHVR-19029 and Favipiravir (HY-14768) synergistically inhibits			

.,,__ОН

он

HO,

HO

0

		the replication of Yellow fever and Ebola viruses in cultured cells ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
In Vivo	IHVR-19029 (5 mg/kg; i L/kg, respectively ^[2] . IHVR-19029 (75/5/5 mg _{max} values of 2.1/0.1/0.	′kg; l.p.; twice daily for 10 days) inhibits EBOV and MARV infection in mice ^[2] . .v.) has AUC, C ₀ , T _{1/2} , CL and V _d values of 1383 μg*h/mL, 1.79 μg/mL, 1.2 hours, 3.49 L/h/kg, and 3.0 g/kg; p.o./i.m./i.p.) has AUC values of 945/1839/983 μg*h/mL, C _{max} values of 0.26/1.23/1.33 μg/ml, T .17 hours, and F values of 4.6/71/133%, respectively ^[2] . ently confirmed the accuracy of these methods. They are for reference only.			
	Animal Model:	BALB/c mice (12 week 233 of age) (MARV infection) ^[2]			
	Dosage:	25, 75 mg/kg			
	Administration:	I.p.; twice daily, until 10 days			
	Result:	Significant protection of Marburg virus (MARV) induced death were observed.			
	Animal Model:	C57B1/6 mice (8–12 week of age) (EBOV infection) ^[2]			
	Dosage:	25, 75 mg/kg			
	Administration:	I.p.; twice daily for 10 days			
	Result:	Significant survival were observed.			

REFERENCES

[1]. Bray M, et al. Meeting report: 31st International Conference on Antiviral Research. Antiviral Res. 2018 Oct;158:88-102.

[2]. Chang J, et al. Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res. 2013;98(3):432-440.

[3]. Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction. ACS Med Chem Lett. 2017 Jan 17;8(2):157-162.

[4]. Ma J, et al. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. Antiviral Res. 2018 Feb;150:112-122.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA